eHealth mHealth HealthTech innovations - Marketing Santé innovant

According to Fard Johnmar, founder and president of Enspektos, pharmaceutical executives are flooded with digital health opportunities and executives and leaders at these firms are having trouble triaging these innovations to determine which ones will meet key organizational, business and health goals.

 

Nevertheless, many drug and device companies are establishing internal innovation groups that are responsible for locating, developing and supporting the integration of digital health technologies into their operations. These companies are form an exclusive "Pharma Digital Health Accelerator Club."

 

This article features several examples of what the pharmaceutical industry is doing to implement disruptive digital innovations that help them manage clinical trials, improve their products, and support healthcare professionals and patients.

 

Contents (partial list):

• Opportunities & Obstacles for Pharma's Use of IoT
• Novo Nordisk Develops Remote Digital Glucose Monitoring Tools
• Top Pharma Companies Establish HCP Technology Standards
• Apple Tightens Health App Rules
• JNJ Innovation Aim: Develop Breakthrough Medical Devices
• Takeda Awards $35K to Digital Startup App for Depression
• JNJ Expands Membership in Digital Innovation Club
• Takeda Joins Pharma Digital Innovation Club
• Important Digital Health Incubators in Europe
• GSK & MIT Test Flumoji - An App That May Provide RWE
• Pfizer Shuns "Next Shiny Thing" When Developing mHealth Apps
• The Potential of Apple's ResearchKit in Clinical Trials
• Google & GSK Team Up to Launch "Bioelectronics Medicine"

 

Download the PDF here.

Via Pharma Guy, Lionel Reichardt / le Pharmageek

Across the life sciences sector, and particularly in pharma, digital innovation is fueling transformation, new opportunities and new challenges. The pace of change means organic strategies alone are not sufficient to build the necessary digital capability. This impact is being felt across the entire value chain. Our recent survey showed that 70% of life sciences CFOs plan to use inorganic approaches to execute their digital strategy.

In the last two years alone, we have seen over 100 “digital deals” involving life science companies (find some here:“The Pharma Digital Health Accelerator Club”; http://sco.lt/5ya2bJ). Tony Drabble and Chris Wayman from our Life Sciences Transaction Advisory Services practice have analyzed these deals and provide their views on where and why we are seeing these deals occur in our latest report, Digital Deals: spotlight on life sciences.

One of the key findings was that digital deals are occurring mainly in one of three areas - digital therapeutics (for new or improved therapies), real-world data (for greater disease insights and patient understanding) and advanced analytics (to maximize value from data). Also, deals involving chronic diseases are experiencing the most digital deal activity, particularly diabetes and respiratory diseases, and nearly half of the deals we observed are seeking to spur innovation and new product development. Across the deals reviewed, a wide variety of deal structures are being employed – the vast majority (approximately 74%) being non-equity-based partnerships and alliances rather than traditional M&A.

Understanding the digital ecosystem, selecting the right partners and structuring deals to both protect intellectual property and extract maximum value are important to success in navigating the digital economy.

 

Via Pharma Guy